

Title (en)
USE OF NICOTINAMIDE MONONUCLEOTIDE (NMN) FOR THE PREVENTION AND/OR TREATMENT OF RHEUMATOID ARTHRITIS, AND
CORRESPONDING COMPOSITIONS

Title (de)
VERWENDUNG VON NIKOTINAMID-MONONUKLEOTID (NMN) ZUR PRÄVENTION UND/ODER BEHANDLUNG VON RHEUMATOIDER
ARTHRITIS UND ENTSPRECHENDE ZUSAMMENSETZUNGEN

Title (fr)
UTILISATION DE NICTOTINAMIDE MONONUCLÉOTIDE (NMN) POUR LA PREVENTION ET/OU LE TRAITEMENT DE LA POLYARTHRITE
RHUMATOÏDE ET COMPOSITIONS CORRESPONDANTES

Publication
EP 4045058 A1 20220824 (FR)

Application
EP 20789620 A 20201015

Priority
• FR 1911696 A 20191018
• EP 2020079014 W 20201015

Abstract (en)
[origin: CA3157656A1] The invention relates to nicotinamide mononucleotide, one of its pharmaceutically acceptable derivatives or one of its pharmaceutically acceptable salts, for use in the prevention and/or treatment of rheumatoid arthritis, as well as to compositions comprising same.

IPC 8 full level
A61K 31/706 (2006.01); **A61K 45/06** (2006.01); **A61P 19/02** (2006.01)

CPC (source: EP US)
A61K 31/706 (2013.01 - EP US); **A61K 45/06** (2013.01 - EP US); **A61P 19/02** (2018.01 - EP US)

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
FR 3102058 A1 20210423; AU 2020367387 A1 20220505; CA 3157656 A1 20210422; CN 114650827 A 20220621; EP 4045058 A1 20220824;
JP 2022552975 A 20221221; US 2024122957 A1 20240418; WO 2021074284 A1 20210422

DOCDB simple family (application)
FR 1911696 A 20191018; AU 2020367387 A 20201015; CA 3157656 A 20201015; CN 202080071907 A 20201015; EP 2020079014 W 20201015;
EP 20789620 A 20201015; JP 2022522323 A 20201015; US 202017768575 A 20201015